Lexicon Pharmaceuticals (LXRX) Cash & Equivalents (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Cash & Equivalents data on file, last reported at $38.1 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $38.1 million, down 39.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $38.1 million (down 39.43% YoY), and the FY2025 annual result was $34.3 million, down 48.5% from the prior year.
• Cash & Equivalents improved to $38.1 million in Q1 2026 per LXRX's latest filing, from $34.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $102.3 million in Q2 2023 and troughed at $18.8 million in Q3 2022.
• A 5-year average of $44.6 million and a median of $35.6 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents slumped 79.55% in 2022, then surged 376.79% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $46.3 million in 2022, then plunged by 51.53% to $22.5 million in 2023, then jumped by 196.71% to $66.7 million in 2024, then slumped by 48.5% to $34.3 million in 2025, then climbed by 10.96% to $38.1 million in 2026.
• Business Quant data shows LXRX's Cash & Equivalents at $38.1 million in Q1 2026, $34.3 million in Q4 2025, and $49.7 million in Q3 2025.